All Oncology News

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

UM171 cell therapy has earned European Commission approval for the treatment of patients with hematologic malignancies requiring HSCT.

Ivonescimab plus chemotherapy improved overall survival in previously treated, advanced non–small cell lung cancer harboring EGFR mutations.

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

R. Lor Randall, MD, FACS, discusses prosthetic design, embodiment strategies, and research to enhance function post-amputation in sarcoma management.

Trastuzumab deruxtecan has been approved in Japan for patients with HR+, HER2-low or -ultralow metastatic breast cancer.

New tool by Yale researchers charts journey from pre-cancerous to advanced disease in animal models.

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

The FDA has granted breakthrough therapy designation to rinatabart sesutecan for the treatment of patients with advanced or recurrent endometrial cancer who have disease progression on or following standard-of-care therapy.

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

Jonathan Leventhal, MD, discusses the prevalence of breast cancer treatment–associated dermatologic AEs and the need for multidisciplinary management.

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.

Meletios A. Dimopoulos, MD, discusses the efficacy and safety of elranatamab plus daratumumab and lenalidomide in transplant-ineligible multiple myeloma.

A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.

Rusfertide earned an FDA breakthrough designation for polycythemia vera based on findings from the phase 3 VERIFY study.

Datopotamab deruxtecan is approved in China for hormone receptor–positive, HER2-negative metastatic breast cancer after prior endocrine therapy and chemotherapy.

Versamune HPV plus pembrolizumab improved OS vs historical data with pembrolizumab in HPV16-positive metastatic HNSCC with a CPS of at least 1.

Marina Kremyanskaya, MD, PhD, discusses the investigation of divesiran in polycythemia vera.

To extend the benefits of CTLA-4 inhibitors to poorly immunogenic tumors such as HCC and CRC, investigators are developing Fc-enhanced CTLA-4 inhibitors.

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

David Olmos, MD, PhD, discusses CAPTURE study findings on the prevalence of HRR mutations in mHSPC, highlighting prognostic impact and outcomes.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

Alberto Martini, MD, discusses the safety of intravesical therapies in NMIBC, the efficacy of EG-70, and future trial needs in this population.

Venetoclax plus obinutuzumab generated safe and efficacious real-world outcomes in first-line CLL with comorbidities.

Researchers call for early screening as young patients live longer.

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

Krystal Biotech will prioritize the development of KB707 as an inhaled formulation for non–small cell lung cancer.